for myelodysplastic syndromes
play

New and Emerging Therapies for Myelodysplastic Syndromes Andrew M. Brunner, MD Massachusetts General Hospital Cancer Center July 21, 2018 Myelodysplastic Syndromes - MDS Bone marrow cancers characterized by dysplasia, clonality, and

0 downloads 2 Views 1,63 MB Size Report
  1. New and Emerging Therapies for Myelodysplastic Syndromes Andrew M. Brunner, MD Massachusetts General Hospital Cancer Center July 21, 2018

  2. Myelodysplastic Syndromes - MDS • Bone marrow cancers characterized by dysplasia, clonality, and ineffective hematopoiesis • Disease of older individuals • Slightly more common among men than women • Survival varies months to years depending on subtype Am J Med. 2012 Jul; 125(7 Suppl): S2 – S5.

  3. MDS is a spectrum of diseases Type and Maturity of Blood cells MDS-RS MDS-del(5q) MDS-EB2 MDS-U MDS-MLD MDS-SLD MDS-EB1 Wong T et al. Nature. 2015 Feb 26; 518(7540): 552 – 555. Variation in Blood Counts Variation in Driver Mutations

  4. MDS treatment is based on disease risk Risk Stratification by IPSS or IPSS-R Blood Counts, Blasts, and Karyotype Risk of Serious or Life-threatening Complication related to MDS: Risk of Progression to Acute Infection Myeloid Leukemia Bleeding IPSS and IPSS-R Risk do not always match the risk of the WHO disease subtype

  5. Updates in Estimating Disease Risk • New understanding about mutations in MDS • Competing risks in often older patients • Changes in MDS risk over time

  6. Recurrent Somatic Mutations Common Mutations: SF3B1 – ringed sideroblasts TET2 SRSF2 ASXL1 DNMT3A RUNX1 U2AF1 TP53 EZH2 IDH2 STAG2 ZRSR2 Blood 2013 122:3616-3627

  7. Mutations are common – and not all MDS! Jaiswal S et al. N Engl J Med 2014; 371:2488-2498

  8. Mutations add to diagnosis and prognosis (and treatment?) Linear Evolution Secondary AML MDS MPN Branching Evolution BMF Therapy De novo AML Clonal Hematopoiesis Healthy Baseline Hematopoiesis Biology of secondary leukemia AM Brunner and TA Graubert. EHA Learning Center. Jun 17, 2018; 219205

  9. Mutations in Healthy Persons and Heart Disease Ebert and Libby. Ann Intern Med. 2018;169(2):116-117.

  10. Competing Risks in MDS Proportion of deaths attributed to MDS/Leukemia, CVD, and Other Causes Proportion of Deaths (%) Brunner et al. Blood Adv. 2017 Oct 18;1(23):2032-2040

  11. Disease Risk: Fixed or Fluctuating? Pfeilstöcker M, et al. Blood 2016 128:902-910

  12. MDS Management MDS Diagnosis Lower Risk Disease Higher Risk Disease Low/INT-1 (INT-2/High or IPSS-R > 4.5) Risk Stratification HCT Not HCT Good QOL, no Single Multiple Candidate Candidate Cytopenia Cytopenias transfusions Induction HMA Transfuse/ HMA Follow CBC Growth Factor CsA/ATG Induction ?Autoimmune Allo-HCT Clinical Trial HMA or Lenalidomide

  13. MDS Management MDS Diagnosis Lower Risk Disease Higher Risk Disease Low/INT-1 (INT-2/High or IPSS-R > 4.5) Risk Stratification MODIFY DISEASE MODIFY SYMPTOMS HCT Not HCT Good QOL, no Single Multiple Candidate Candidate Cytopenia Cytopenias transfusions Transfusion Induction HMA Risk of Death and Transfuse/ HMA Follow CBC Growth Factor Dependence CsA/ATG AML Induction ?Autoimmune Allo-HCT Clinical Trial HMA or Lenalidomide

  14. MDS Management Lower Risk Disease Specific Cytopenia 5q- Syndrome Low/INT-1 MODIFY SYMPTOMS Good QOL, no Single Multiple Cytopenia Cytopenias transfusions EPO Level Transfusion Dependence Transfusion Transfuse/ Follow CBC Growth Factor Dependence CsA/ATG ?Autoimmune Neutropenia Hypoplastic MDS/AA HMA or Lenalidomide

  15. MDS Management More Immediate Risk of Death Due to Disease Higher Risk Disease or AML (INT-2/High or IPSS-R > 4.5) MODIFY DISEASE HCT Not HCT Candidate Candidate Transplant Candidacy Risk of Death and Induction HMA HMA AML Induction Allo-HCT Chemotherapy Clinical Trial

  16. MDS Management – Integrating Many Factors “Targetable” Time AML Risk Mutations ? Transfusion Toxicity Travel Needs Profile

  17. Therapeutic Targets in MDS Sallman et al. Clinical Lymphoma, Myeloma & Leukemia, 2017-10-01, Volume 17, Issue 10, Pages 613-620

  18. T-cell New Therapies to Target MDS TGFB • Pathway Driven • TGF- β pathway • Immune Checkpoint Blockade • Apoptosis – Bcl2 SMAD2/3 SMAD4 • Mutation Driven • Spliceosome mutations 2HG • Mutated IDH enzymes CytoC

  19. T-cell New Therapies to Target MDS TGFB • Pathway Driven • TGF- β pathway • Immune Checkpoint Blockade • Apoptosis – Bcl2 SMAD2/3 SMAD4 • Mutation Driven • Spliceosome mutations 2HG • Mutated IDH enzymes CytoC

  20. TGF-B Ligand Traps and Erythropoiesis Paulson RF. Nature Medicine volume20, pages334 – 335 (2014) Blank U and Karlsson S. Blood 2015 125:3542-3550

  21. Luspatercept • Activin receptor IIIB protein, TGFB family member ligand trap • EPO >500 or intolerant of ESAs, no prior HMA Platzbecker U et al. Lancet Oncology Volume 18, Issue 10, October 2017, Pages 1338-1347

  22. T-cell New Therapies to Target MDS TGFB • Pathway Driven • TGF- β pathway • Immune Checkpoint Blockade • Apoptosis – Bcl2 SMAD2/3 SMAD4 • Mutation Driven • Spliceosome mutations 2HG • Mutated IDH enzymes CytoC

  23. Immune Checkpoints in Cancer Pardoll DM. Nature Reviews Cancer 2012;12, 252-264 Ribas A. N Engl J Med 2012;366:2517-2519.

  24. DNMTI and Interferon Response Ovarian cell lines • increased expression of endogenous retroviral transcripts (ERVs) • increases dsRNA • CTLA-4 + AZA synergistic in a mouse melanoma model Chiappinelli et al. Cell 2015;162:974

  25. PD-L1 in MDS • PD-L1 is upregulated in MDS blasts after exposure to IFNy and TNFa Proliferative MDS cells are PD-L1+ Kondo et al. Blood 2010 116:1124-1131

  26. T-cell New Therapies to Target MDS TGFB • Pathway Driven • TGF- β pathway • Immune Checkpoint Blockade • Apoptosis – Bcl2 SMAD2/3 SMAD4 • Mutation Driven • Spliceosome mutations 2HG • Mutated IDH enzymes CytoC

  27. Apoptosis in MDS • BCL2 is a regulator of apoptosis • “priming” apoptosis may be attractive in treating MDS Letai A. CCR. Volume 21, Issue 22, pp. 5015-5020 Roberts AW et al. CCR. Volume 23, Issue 16, pp. 4527-4533

  28. T-cell New Therapies to Target MDS TGFB • Pathway Driven • TGF- β pathway • Immune Checkpoint Blockade • Apoptosis – Bcl2 SMAD2/3 SMAD4 • Mutation Driven • Spliceosome mutations 2HG • Mutated IDH enzymes CytoC

  29. Spliceosome mutations in MDS Joshi et al. Blood 2017 129:2465-2470

  30. Possible Spliceosome Targets Agrawal et al. Current Opinion in Genetics & Development Volume 48, February 2018, Pages 67-74

  31. T-cell New Therapies to Target MDS TGFB • Pathway Driven • TGF- β pathway • Immune Checkpoint Blockade • Apoptosis – Bcl2 SMAD2/3 SMAD4 • Mutation Driven • Spliceosome mutations 2HG • Mutated IDH enzymes CytoC

  32. Targeting mutated IDH proteins http://targetedcancercare.massgeneral.org/My-Trial-Guide/Diseases/Leukemias/IDH2.aspx

  33. Conclusions • Our understanding of MDS has grown significantly • This knowledge may help us to identify new targets for treatment • A number of therapies are in development and have exciting potential • New targets continue to be identified • Questions? abrunner@partners.org

Recommend Documents


mds
MDS The Stuart Goldberg MD

What you need to know about MDS The Stuart Goldberg MD Myelodysplastic

myelodysplastic syndromes
Myelodysplastic syndromes Overview of

Myelodysplastic Syndromes: Disclosures Update on Classification and None

update on diagnosis of myelodysplastic syndromes
Update on Diagnosis of Myelodysplastic

Update on Diagnosis of Myelodysplastic Syndromes Jay L. Patel, MD Disclosure

myelodysplastic syndromes what is on the horizon
Myelodysplastic Syndromes What is on

Myelodysplastic Syndromes What is on the horizon? Rami Komrokji, MD Senior

with lower risk myelodysplastic syndromes mds
With Lower-Risk Myelodysplastic

Luspatercept Response in New Subpopulations of Patients With Lower-Risk

luspatercept response in new subpopulations of patients
Luspatercept Response in New

Luspatercept Response in New Subpopulations of Patients With Lower-Risk

best practices and emerging therapies for myelodysplastic
Best Practices and Emerging Therapies

Best Practices and Emerging Therapies for Myelodysplastic Syndromes Erica

myelodysplastic syndromes mds
Myelodysplastic Syndromes (MDS)

Early Treatment Initiation in Myelodysplastic Syndromes (MDS) Produces Higher

myelodysplastic syndromes chaos and order del 5q syndrome
MYELODYSPLASTIC SYNDROMES: CHAOS AND

MYELODYSPLASTIC SYNDROMES: CHAOS AND ORDER Del (5q) Syndrome Dr Valeria Di

leukemia myelodysplastic
Leukemia & Myelodysplastic

Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes,

determination of the recommended phase 2 dose of
Determination of the Recommended Phase

Determination of the Recommended Phase 2 Dose of birinapant in combination

pharmacological inactivation of skp2 scf ubiquitin ligase
Pharmacological Inactivation of Skp2

Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer

proof of mechanism based on target engagement and
Proof-of-Mechanism Based on Target

Proof-of-Mechanism Based on Target Engagement and Modulation of Gene

cell death molecular mechanisms and
cell death: molecular mechanisms and

COST 844: Apoptosis and programmed cell death: molecular mechanisms and

bay area rsi igem 2008 team
Bay Area RSI iGEM 2008 Team Joshua

Bay Area RSI iGEM 2008 Team Joshua Resa, Stanford University Sean Allen, UC

modeling cell life and cell death in cancer
Modeling cell life and cell death in

Modeling cell life and cell death in cancer Andrei Zinovyev Computational

tom40 and the mt upr
Tom40 and the mt(UPR) Sonal Gagrani

Tom40 and the mt(UPR) Sonal Gagrani Gottschalk Lab TOMM40 encodes for the

tomorrow s innovation changing r amp d model in life
Tomorrow's Innovation: Changing

Tomorrow's Innovation: Changing R&D Model in Life Sciences Jim Sullivan,

activatable molecular probes for optical imaging
Activatable Molecular Probes for

Activatable Molecular Probes for Optical Imaging Ick Chan Kwon, Ph.D.

structure function analysis of the inositol trisphosphate
Structure-function analysis of the

Structure-function analysis of the inositol trisphosphate receptor and its

approaches to identifying approaches to identifying
Approaches to Identifying Approaches

Approaches to Identifying Approaches to Identifying Possible Mechanisms of

novel therapeutic for healing gut tissue novel
Novel Therapeutic for Healing Gut

Novel Therapeutic for Healing Gut Tissue Novel Therapeutic for Healing Gut